Sign In
Buy FEMY
$2.86
-0.0500 (-1.72%)
At Close: Jul 31, 2026
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
09:00am, Thursday, 11'th Sep 2025
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- -- Following the Setup Kit, th
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
11:44pm, Monday, 25'th Aug 2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwi
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
06:16pm, Friday, 08'th Aug 2025
Femasys Inc. (FEMY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.21 per share a year ago.
Femasys Revenue Jumps 85 Percent in Q2
05:22pm, Friday, 08'th Aug 2025
Femasys Revenue Jumps 85 Percent in Q2
Femasys Announces Second Quarter Financial Results for 2025
04:05pm, Friday, 08'th Aug 2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innova
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
09:00am, Wednesday, 06'th Aug 2025
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biome
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
09:00am, Wednesday, 25'th Jun 2025
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disrup
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
09:00am, Tuesday, 17'th Jun 2025
--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed ® , and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Fema
-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leadin
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
04:23pm, Thursday, 29'th May 2025
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwid
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
08:00pm, Thursday, 08'th May 2025
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
05:01pm, Thursday, 08'th May 2025
-- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed ® for first-line infertility treatment and FemBloc ® non-surgical permanent birth control (fu
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
11:10am, Thursday, 27'th Mar 2025
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago.
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
09:00am, Thursday, 27'th Mar 2025
-- Company expands commercial product offering with FemBloc ® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025
